MedTrace Logo

Effect of Intrathecal Clonidine in Hypertensive Subjects With Poorly Controlled Blood Pressure

NCT01297335 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-10-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the acute efficacy of intrathecal clonidine to reduce blood pressure in hypertensive subjects with poor blood pressure control and describe its effects on cardiovascular function.

Conditions

Interventions

DRUG

clonidine

Intrathecal Clonidine

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • The Center for Clinical Research, Winston-Salem, NC

    lead OTHER

Principal Investigators

  • Richard L. Rauck, MD · Owner

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-07-31
Completion
2012-07-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01297335 on ClinicalTrials.gov